Back to News
Market Impact: 0.15
New Peptide ETF From REX Looks Beyond GLP-1 Drugs
Source: etftrends.com
Healthcare & BiotechProduct Launches
REX launched a new peptide ETF that tracks 36 peptide-linked companies, including GLP-1 drugmakers and businesses involved in making and delivering treatments, as well as device and supplement makers. The article provides no fund-performance data or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Razer’s CEO waited 20 years for everyone to become a gamer. He says AI is finally making it happen
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Tech giants race to get AI gadgets on shelves for holiday rush
- Electric vehicle sales in the U.S. are showing signs of life
- Delta knows the top 40% of Americans are $40 trillion richer than just a few years ago. Cue new burgers and bourbon on Delta One’s biggest revamp yet